Back to School: How biopharma can reboot drug development. Access exclusive analysis here

StreptAvax: IDBE said that in a dose-escalation 30-patient Phase I study, a 50 mg dose of the vaccine was safe and well tolerated in all 10 patients receiving t

ID Biomedical Corp. (IDBE; TSE:IDB), Vancouver, B.C.
Product:

Read the full 89 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE